-
2023-506854-19-00
1
2022-05-19
Solid Tumors
-
2023-506359-68-00
5
2022-04-08
Active Proliferative Lupus Nephritis
-
2023-504597-37-00
5
2022-03-25
Focal segmental glomerulosclerosis
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2023-505696-74-00
5
2022-02-10
systemic lupus erythematosus
-
2023-504884-17-00
5
2022-02-04
Proteinuria
-
2023-506867-33-01
4
2022-01-25
Chronic Hepatitis B
-
2023-509028-17-00
5
2022-01-06
Alagille Syndrome
-
2023-507974-42-00
4
2021-12-01
Moderate to Severe Ulcerative Colitis
-
2023-507342-84-00
5
2021-10-26
Bladder Cancer
-
2022-503105-38-00
5
2021-10-22
MET-driven, unresectable and locally advanced or metastatic Papillary
-
2024-513031-24-00
10
2021-10-22
Moderate-to-severe Systemic Lupus Erythematosus (SLE)
-
2024-513091-17-00
5
2021-09-29
Progressive myopia
-
2024-513770-22-00
4
2021-09-22
Malignant Solid Tumors - Non Small Cell Lung Cancer
-
2023-508690-92-00
11
2021-09-20
IgA Nephropathy
-
2024-516959-40-00
4
2021-08-17
This trial evaluates the efficacy and safety of Mirvetuximab soravtans
-
2024-511321-54-00
5
2021-08-04
intermediate-high-risk acute pulmonary embolism
-
2023-505641-12-00
5
2021-07-27
Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation
-
2024-516754-22-00
4
2021-07-14
Pulmonary Arterial Hypertension (PAH)
-
2023-505089-27-00
5
2021-07-01
Atypical Hemolytic Uremic Syndrome (aHUS)
-
2023-504997-39-00
5
2021-06-14
Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
-
2024-510588-53-00
11
2021-06-10
Treatment of patients with HER2-positive breast cancer with or without
-
2024-513227-16-00
5
2021-05-19
Immunoglobulin A Nephropathy (IgAN)
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer